Reinsurance Dependency Risk in Indian Health Insurance

Indian health insurance gross written premium crossed INR 1.1 lakh crore in FY 2025, growing at roughly 22% compounded over the past five years, well ahead of capital deployed by the standalone health insurers and the health books of multi-line general insurers. The growth has been absorbed by reinsurance. Cession rates for retail health business at several standalone health insurers exceed 40% of gross premium, and group health books frequently cede higher proportions where claim experience is volatile.

Reinsurance has been a feature of Indian health insurance for as long as the line has existed, but the scale of dependency is new. Three drivers have intensified it: post-COVID claim inflation, accelerated retail digital distribution that has outpaced underwriting maturity, and IRDAI's push for higher sum-insured ceilings on retail products without parallel capital uplift on the primary side.

The Indian reinsurance market for health is structurally concentrated. GIC Re retains a statutory obligatory cession position (currently 4% of every general insurance treaty), and is also the single largest commercial reinsurer for Indian health business. After GIC Re, a small number of foreign branch reinsurers (Munich Re, Swiss Re, SCOR, Hannover Re, RGA on the life-health side) and the GIFT City IFSC-registered reinsurers account for the bulk of remaining capacity.

For an Indian health insurer, this concentration means three things:

• treaty renewal terms are negotiated against a small panel of counterparties with shared market intelligence
• a deterioration in any single reinsurer's appetite materially affects the insurer's capacity
• pricing for difficult risk segments (senior citizens, high-end retail, complex group) is set effectively by reinsurer view rather than insurer pricing

The IRDAI (Reinsurance) Regulations, 2018, amended through 2024, structure the cession order: Indian reinsurers first, IFSC registrants next, foreign branch reinsurers thereafter, and cross-border reinsurers last. The intent is to retain risk and premium in India. The practical result is that GIC Re's terms anchor the market.

Global reinsurance pricing hardened materially in 2023 and 2024 across most lines, driven by catastrophe losses, claim inflation, and elevated interest-rate expectations. Health was less affected than property catastrophe, but the 2025 January and April renewals showed clear signs of tightening for Indian health:

• higher quota-share retentions required on retail business, pushing more risk onto primary balance sheets
• revised stop-loss attachment points for group business, tightening insurer protection against bad years
• commission reductions on treaty business, compressing insurer margins
• stricter underwriting conditions including required medical-history disclosures, age-based loadings, and disease-specific sub-limits

For primary insurers, the consequence has been a margin squeeze. For policyholders, the consequence has been visible: senior-citizen premiums rising 25 to 40% at renewal, more aggressive medical screening at sum-insured uplifts, and tighter waiting-period interpretations on pre-existing conditions.

Indian health insurers typically use a mix of treaty structures, each carrying different dependency profiles.

• Quota share cedes a fixed proportion of every premium and claim. Simple, but creates the largest dependency because every rupee of growth requires reinsurer appetite.
• Surplus cedes the portion of risk above the insurer's retention on each policy. Allows the insurer to retain smaller risks fully and cede only the part it cannot bear.
• Excess of loss (XL) pays reinsurance recoveries above a defined attachment point on a per-event or per-policy basis. Protects against severity rather than frequency.
• Aggregate stop-loss caps total claims for a defined period or portfolio. Protects against systemic deterioration.

Most Indian health insurers combine quota share with stop-loss or excess of loss. The treaty mix determines how dependency translates into actual financial exposure. A quota-share-heavy treaty makes the insurer's growth proportional to reinsurer appetite. A stop-loss-heavy treaty leaves the insurer carrying more attritional risk but with capped tail. Choosing the right mix is a strategic decision, not a technical placement question.

Pradhan Mantri Jan Arogya Yojana (PMJAY) and state-level Ayushman Bharat schemes are reshaping Indian health insurance reinsurance economics in ways most analysts miss. The public schemes are partially insured and partially run on trust-model financing, but the empanelled insurers running state implementations carry significant exposure that flows into the same reinsurance market.

For private insurers participating in PMJAY or state schemes:

• the same treaty often covers retail, group, and government-scheme business, blending the loss experience
• claim-frequency shocks in the scheme business (mass-event admissions, fraud waves, hospital-network disputes) cascade into the treaty
• the political economy of scheme pricing creates persistent margin pressure that reinsurers price into treaty terms

Insurers that participate heavily in PMJAY without ring-fencing the treaty exposure are taking on a hidden concentration: their retail policyholders effectively subsidise scheme economics, and reinsurers know it. Several insurers have begun separating scheme treaties from commercial treaties to address this.

Reinsurance is not free of counterparty risk. The 2008-2009 financial crisis saw AIG, then a major reinsurer, require US government rescue, and several smaller reinsurers exit lines under stress. Indian health insurers were limited counterparties at that time. They are not now.

Reinsurance counterparty management for an Indian health insurer should cover:

• minimum credit ratings for each reinsurer participating in the treaty, typically A or better from S&P/AM Best or local equivalents
• concentration limits capping any single reinsurer at a defined proportion (often 25 to 35% of total reinsurance recoverable)
• collateral or letters of credit for reinsurers outside the highest rating brackets
• ongoing monitoring of reinsurer financial strength and any IRDAI or home-regulator interventions

The IRDAI's 2024 amendments to the Reinsurance Regulations strengthened these expectations. The board should see a reinsurance counterparty report at least annually, with the chief risk officer reviewing concentrations and credit positions before each major treaty renewal.

Reducing reinsurance dependency is not an end in itself; the question is whether the dependency is structured well and whether the insurer is building optionality.

Four moves materially improve the position over a 3 to 5 year horizon.

First, selectively increase retention on segments with mature loss data and lower volatility (mid-market group, mid-tier retail) while keeping reinsurance support for senior citizens, high-end retail, and government scheme business. This concentrates dependency where it actually pays off.

Second, diversify reinsurer panels. Add at least one IFSC-registered reinsurer and one additional foreign branch reinsurer to broaden negotiating position and reduce single-counterparty risk.

Third, invest in claims and underwriting analytics to demonstrate experience improvements to reinsurers. Better data improves treaty terms more reliably than negotiation strategy.

Fourth, build capital deliberately. The IRDAI's solvency framework allows higher retention as capital strengthens. Insurers that fund growth purely through reinsurance dependency are running a model that hardens against them when the cycle turns. Capital and reinsurance should be complementary, not substitutes.